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Highlights 
 Co-trimoxazole use in UK is dramatically lower than in the late 1980s 
 In older studies, decline in use did not result in decline in resistance 
 Mathematical models showed that it may take decades before resistance declines 
 Analysed more recently collected Escherichia coli blood isolates 
 Co-trimoxazole resistance did not decline over time between 2002 and 2014 
 
Abstract 
Objective: Several studies showed that a substantial decline in the use of co-trimoxazole did not 
result in a decline in resistance rates among Escherichia coli isolates. Since mathematical models 
have shown that it may take decades before resistance rates start to decline to relevant levels, we 
performed a new analysis using more recently collected data. 
Methods: Data were extracted from Guy’s and St Thomas’ Hospitals Transmission and Antimicrobial 
Record database which contains microbiological test results from all specimens tested between 2002 
and 2014. We selected all blood samples positive for E. coli which were tested for resistance against 
co-trimoxazole. Prevalence of co-trimoxazole resistance among the tested samples by year was 
modelled by a Poisson model.   
Results: Almost all (96%) of E. coli blood isolates were tested for co-trimoxazole resistance. In total, 
2,070 E. coli isolates were available for analyses. Resistance to co-trimoxazole fluctuated over the 
years, but there was no clear increasing or decreasing trend; the annual percentage change in the 
prevalence of co-trimoxazole resistance was 0.52 (95% confidence interval -0.75% to 1.81%).  
Including co-trimoxazole or trimethoprim use in the year before the sample was taken did not improve 
the model. 
Conclusion: The prevalence of co-trimoxazole resistance among E. coli blood isolates remained 
high, almost three decades after a substantial decline in co-trimoxazole use. Our results further 
emphasize the importance of prudent antibiotics use, as antibiotic resistance may not always be 
easily reversible. 
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1. Introduction 
There is a clear link between antimicrobial consumption within a population and the resistance rates 
of bacteria in that same population. Countries with relatively high antibiotic prescribing rates have 
relatively high antibiotic resistance rates [1], geographical variation within countries can be 
explained by variation in antibiotic use [2], and individuals recently exposed to antibiotics have a 
higher likelihood of carrying resistant bacteria [3]. 
  
Although there are no doubts about the causal link between antibiotic consumption and antibiotic 
resistance, there is debate about the reversibility of antibiotic resistance [4]. In light of the lack of 
new antibiotic development, lowering resistance by more prudent use of antibiotics could be an 
important strategy to help tackling the growing threat of antibiotic resistance. If many resistances 
were not reversible, the prudent use of antibiotics to prevent a further resistance development and 
rise in resistance levels would be even more important.  
 
Theoretically, when selective pressure brought about by antibiotic prescribing is reduced, resistant 
bacteria would be outcompeted by susceptible bacteria, because carrying resistance genes is 
generally assumed to be associated with a fitness cost [5]. In line with this theory, reducing 
antimicrobial use appears to have been fairly successful in reducing the prevalence of resistance in 
confined environments, such as hospital wards or in intensive farming [5]. However, a major part of 
the apparent successes in hospital settings may be explained by a dilution effect caused by 
continuous influx of patients who are infected or colonized with susceptible bacteria [5]. In essence, 
susceptible bacteria from these patients replace the resistant bacteria [5].  
 
Reducing resistance in bacteria considered as commensal flora, such as Escherichia coli, has been 
proven to be much harder [6]. There are several reasons why resistance may not be easily reversible: 
i) some resistances are associated with relatively low or non-existent fitness costs; ii) compensatory 
evolution may reduce fitness costs; and iii) resistance genes are frequently collocated with other 
resistance genes (to other antimicrobial classes) on the same plasmid causing co-selection [4,6]. In 
addition, mathematical models have shown that, even with complete cessation of antibiotic use, it 
may simply take years or even decades before resistance in the community will decline to clinically 
relevant levels [5]. 
 
Previously, a study from the Royal London Hospital showed that a huge decline in the use of co-
trimoxazole (trimethoprim/sulfamethoxazole) did not result in a decline in sulfonamide resistance 
rates among E. coli isolates within 9 years [6]. The combination of low fitness costs or even increased 
fitness in one strain and co-selection by other antimicrobials are thought to be the main reasons 
behind the lack of a decline in sulphonamide resistance [7]. In a study from Sweden, a 2-year drastic 
reduction in trimethoprim use had almost no effect on the frequency of trimethoprim and co-
trimoxazole resistance rates [8]. Similarly, rates of co-trimoxazole resistance among E. coli samples 
remained stable despite significant decreases in co-trimoxazole use in the community in studies 
from Switzerland [9], Sweden [10, 11], and Spain [12].  
 
Because mathematical models have shown that it may take several years or even decades before 
resistance rates start to decline to clinically relevant levels [5], and several years have passed since 
the previous studies assessed co-trimoxazole resistance levels, we performed a new analysis using 
more recently collected data.  
 
2. Methods 
2.1 Antibiotic prescribing 
Data on national annual primary care antibiotic prescriptions between 1998 and 2013 were obtained 
from NHS Business services authority (NHSbsa). The data includes all antibiotics prescribed in 
England which were dispensed in the community, except items prescribed by dentists or by 
hospitals. UK Veterinary sales of trimethoprim/sulfonamides were obtained from the UK Veterinary 
Antibiotic Resistance and Sales Surveillance reports of the Veterinary Medicines Directorate [13].  
 
2.2 Bacterial isolates 
Data were extracted from Guy’s and St Thomas’ Hospitals (London, UK) Transmission and 
Antimicrobial Record database which contains microbiological test results from all specimens tested 
between 2002 and 2014. This collection contains specimens from inpatients, outpatients, accident 
and emergency departments, and general practice patients within the hospitals’ catchment area. 
National Ethical approval for research databases is not required under the Research Governance 
Framework as directed by the Health Research Authority, UK. We selected all blood samples positive 
for E. coli which were tested for resistance against co-trimoxazole. We only included the first isolate 
of a specific species for each patient in each year [6]. During the entire period, zone diameter 
breakpoints were ≤15 (resistant) and ≥16 (susceptible) [14].  
 
2.3 Statistical analyses 
Prevalence of co-trimoxazole resistance among the tested samples by year was modelled by taking 
the count of co-trimoxazole resistant samples as the response variable in a Poisson model with 
robust standard errors [15]. To take into account that the number of tests may differ per year, the 
natural logarithm of the number of samples tested for co-trimoxazole resistance each year was 
included as an offset variable. Initially, a model with only time (calendar year – 2002) was considered 
as a predictor variable. Potential non-linear effect of time was taken into account by including an 
additional quadratic function for time into the model. Subsequently, we evaluated whether including 
co-trimoxazole items dispensed per 100,000 inhabitants, trimethoprim items dispensed per 100,000 
inhabitants, or veterinary sales of trimethoprim/sulfonamides (tonnes active ingredient) in the year 
before improved the model. Finally, it was evaluated whether there was a delayed (or lagged) 
association between co-trimoxazole or trimethoprim use and co-trimoxazole resistance. Because 
antibiotic dispensing data was available up to 3 years before the first resistant measurements, we 
evaluated whether the model fit improved by including 1, 2 and 3 year lagged measurements for co-
trimoxazole use , trimethoprim use, and veterinary trimethoprim/sulphonamide sales 
simultaneously using an unconstrained distributed lag model [15]. The best-fitting model was 
obtained using backward stepwise regression based on the Akaike Information Criterion (AIC).  
Partial autocorrelation function plots were used to check for residual autocorrelation in the Poisson 
models. The percentage annual change in prevalence of co-trimoxazole resistance was estimated 
using the formula (exp(β)-1)*100, where β refers to the sum of the relevant parameter estimates 
form the Poisson model.  We used R 3.2.1 for all our statistical analyses. 
 
3. Results  
3.1 Antibiotic prescribing 
A substantial decline in sulfonamide use, largely driven by a switch from co-trimoxazole to 
trimethoprim only, has been observed in the UK. While there were over 4 million annual 
prescriptions in the late 1980s, the use declined to 320,000 in 1991, and remained below 70,000 
between 2000 and 2004 [6,7]. The data for England between April 1998 and March 2013 indicate 
that annual co-trimoxazole prescriptions initially declined to 47,000 in 2002, but thereafter 
increased again to 99,000 prescriptions in 2013 (Figure 1). Nevertheless, the total number of co-
trimoxazole prescriptions is still substantially lower than in the 1980s. There was also an increase in 
annual trimethoprim prescriptions, from 2.7 million in 2002 to 3.8 million in 2013 (Figure 1). 
Veterinary sales of trimethoprim/sulfonamides decreased between 1999 and 2013 (Figure 2).   
 
3.2 Co-trimoxazole resistance rates  
Almost all (96%) of E. coli blood isolates were tested for co-trimoxazole resistance. After removing 
repeated blood samples retrieved from patients within one year (i.e. 2nd, 3rd,  ..nth sample),  2,070 E. 
coli isolates were available for analyses. Resistance to co-trimoxazole fluctuated over the years, but 
there was no clear increasing or decreasing trend (Figure 3). The absence of a clear trend was also 
reflected by the fact that the best fitting model only included an intercept. Including co-trimoxazole 
or trimethoprim use, or veterinary trimethoprim/sulfonamides sales in the 1-3 years before the 
sample was taken did not improve the model fit, as evidenced by higher AIC values being obtained 
when adding these variables to the model. When time in calendar years was forced into the model, 
the annual percentage change in the prevalence of co-trimoxazole resistance was 0.52% (95% 
confidence interval -0.75% to 1.81%). Partial autocorrelation function plots indicated that there was 
no significant residual autocorrelation.  
 
 
4. Discussion 
Although co-trimoxazole prescribing increased compared to the previous decade in England, 
prescribing levels are still dramatically lower than those observed in the late 1980s. Nevertheless, 
similarly to previous studies from England that did not observe an effect on sulfonamide resistance 
[6,7], we did not observe a decrease in co-trimoxazole resistance among E. coli blood isolates. 
However, it is of note that the recent slight increase in consumption of co-trimoxazole did not result 
in an increase in co-trimoxazole resistance among E. coli blood isolates.  
 
Reasons explaining why co-trimoxazole and sulfonamide resistance remained high in several 
countries despite a dramatic decrease in co-trimoxazole use have been discussed extensively 
[4,6,7,10-12]. One suggested explanation was that there may be a considerable time delay (even 
decades) before reductions in use are mirrored by reductions in resistance. Our results, together 
with other older studies [4,6,7,9-11], suggest that time since the decline in co-trimoxazole use is not 
a major factor determining the prevalence of co-trimoxazole resistance among E. coli isolates. Likely 
explanations for rather stable levels of resistance are co-selection by continued prescribing of other 
antibiotics and relatively low or non-existent fitness costs [6,16]. For example, trimethoprim is still 
widely used in the community and may partly explain continued high co-trimoxazole, a combination 
of trimethoprim and sulfamethoxazole, resistance rates. Although common resistance genes against 
trimethoprim do not confer resistance against sulfonamides [17], the genes conferring the resistance 
against trimethoprim, dfr, and sulphonamides, sul, are often linked in the widely distributed class 1 
integrons [17, 18]. 
 
An important strength of this study is that the MCS database allowed us to perform analyses based 
on more than 2,000 blood isolates obtained from consecutive years, reducing the likelihood that 
findings are due to random variation in some selected years. 
  
The current study has some important limitations however. In the database, the actual minimum 
inhibitory concentrations (MICs) or zone diameters are not stored. Hence, it was not possible to 
evaluate whether there were changes in the average MIC. Similarly, it was not possible to estimate 
the prevalence of co-trimoxazole resistance among urinary samples as those types of samples were 
not regularly tested for co-trimoxazole resistance.  
In addition, we only had information about community antibiotic prescriptions on the national level, 
rather than at a regional or more granular level (which would have enabled us to determine 
prescribing within the catchment population of the hospitals form which resistance rates were 
determined). However, although there may be some geographical variation, given the magnitude of 
the reduction in national prescribing rates, it is almost certain that the conclusion that co-
trimoxazole prescriptions are substantially lower than in the 1980’s also holds for the catchment 
area of Guy’s and St Thomas’ Hospitals.  
We did not have information about co-trimoxazole dispensed in the hospitals. However, the majority 
of antibiotics are dispensed in primary care [19] and co-trimoxazole is not commonly used in English 
hospitals [20], thereby limiting the potential impact of changes in hospital prescribing. We cannot 
exclude the possibility that local co-trimoxazole resistance rates were partly influenced by 
intercontinental travel to areas with high co-trimoxazole use and resistance rates. Nevertheless, 
given the fact that similar observations have been made using older data in the UK and other 
countries [4,6,7,9-11], results from this local hospital are likely generalizable to the national level.   
 
In conclusion, the prevalence of co-trimoxazole resistance among E. coli blood isolates remained 
high almost three decades after a substantial decline in co-trimoxazole use. Our results further 
emphasize the importance of prudent antibiotics use, as antibiotic resistance may not always be 
easily reversible.  
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Figure 1. Annual co-trimoxazole (dots) and trimethoprim (squares) prescriptions in England.  
 
 
 
 
Figure 2. Annual trimethoprim/sulfonamides sales for veterinary use in the UK. 
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 Figure 3. Annual proportion of E. coli blood isolates resistant to co-trimoxazole.  
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